Dextran is a low molecular weight dextran used as an adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma, as well as the prophylaxis of venous thrombosis and pulmonary embolism during high-risk medical procedures. Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links.
- Mechanism
- Curator reviewed · 1 reference
In preclinical studies, the mechanism of action is thought to be related to the blockage of the uptake of tissue plasminogen activator by mannose-binding receptors. This process has a direct effect by enhancing endogenous fibrinolysis.
- Primary indication
- Dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration.Curator reviewed · 16 structured indications
- First approval
- Canada, 1998 · United States, 2005
- Brand names
Resolves to
What you can answer from here — as of September 12, 2026
Which drugs share a target with Dextran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account